• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

参与促红细胞生成素治疗减少心血管事件试验(TREAT)的糖尿病慢性肾脏病患者的死亡原因

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

作者信息

Charytan David M, Lewis Eldrin F, Desai Akshay S, Weinrauch Larry A, Ivanovich Peter, Toto Robert D, Claggett Brian, Liu Jiankang, Hartley L Howard, Finn Peter, Singh Ajay K, Levey Andrew S, Pfeffer Marc A, McMurray John J V, Solomon Scott D

机构信息

Renal Division, Department of Medicine, Brigham & Women's Hospital, Boston, MA.

Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, Boston, MA.

出版信息

Am J Kidney Dis. 2015 Sep;66(3):429-40. doi: 10.1053/j.ajkd.2015.02.324. Epub 2015 Apr 29.

DOI:10.1053/j.ajkd.2015.02.324
PMID:25935581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4549188/
Abstract

BACKGROUND

The cause of death in patients with chronic kidney disease (CKD) varies with CKD severity, but variation has not been quantified.

STUDY DESIGN

Retrospective analysis of prospective randomized clinical trial.

SETTING & PARTICIPANTS: We analyzed 4,038 individuals with anemia and diabetic CKD from TREAT, a randomized trial comparing darbepoetin alfa and placebo.

PREDICTORS

Baseline estimated glomerular filtration rate (eGFR) and protein-creatinine ratio (PCR).

OUTCOMES

Cause of death as adjudicated by a blinded committee.

RESULTS

Median eGFR and PCR ranged from 20.6 mL/min/1.73 m(2) and 4.1 g/g in quartile 1 (Q1) to 47.0 mL/min/1.73 m(2) and 0.1 g/g in Q4 (P<0.01). Of 806 deaths, 441, 298, and 67 were due to cardiovascular (CV), non-CV, and unknown causes, respectively. Cumulative CV mortality at 3 years was higher with lower eGFR (Q1, 15.5%; Q2, 11.1%; Q3, 11.2%; Q4, 10.3%; P<0.001) or higher PCR (Q1, 15.2%; Q2, 12.3%; Q3, 11.7%; Q4, 9.0%; P<0.001). Similarly, non-CV mortality was higher with lower eGFR (Q1, 12.7%; Q2, 8.4%; Q3, 6.7%; Q4, 6.1%; P<0.001) or higher PCR (Q1, 10.3%; Q2, 7.9%; Q3, 9.4%; Q4, 6.4%; P=0.01). Sudden death was 1.7-fold higher with lower eGFR (P=0.04) and 2.1-fold higher with higher PCR (P<0.001). Infection-related mortality was 3.3-fold higher in the lowest eGFR quartile (P<0.001) and 2.8-fold higher in the highest PCR quartile (P<0.02). The overall proportion of CV and non-CV deaths was not significantly different across eGFR or PCR quartiles.

LIMITATIONS

Results may not be generalizable to nondiabetic CKD or diabetic CKD in the absence of anemia. Measured GFR was not available.

CONCLUSIONS

In diabetic CKD, both lower baseline GFR and higher PCR are associated with higher CV and non-CV mortality rates, particularly from sudden death and infection. Efforts to improve outcomes should focus on CV disease and early diagnosis and treatment of infection.

摘要

背景

慢性肾脏病(CKD)患者的死因随CKD严重程度而异,但这种差异尚未被量化。

研究设计

对前瞻性随机临床试验进行回顾性分析。

研究地点与参与者

我们分析了来自TREAT研究的4038例贫血和糖尿病性CKD患者,该研究是一项比较达比加群酯和安慰剂的随机试验。

预测因素

基线估计肾小球滤过率(eGFR)和蛋白肌酐比值(PCR)。

研究结果

由盲法委员会判定的死因。

结果

eGFR和PCR的中位数在第1四分位数(Q1)中为20.6 mL/min/1.73 m²和4.1 g/g,在第4四分位数(Q4)中为47.0 mL/min/1.73 m²和0.1 g/g(P<0.01)。在806例死亡病例中,分别有441例、298例和67例死于心血管(CV)、非CV和不明原因。3年时,eGFR较低(Q1,15.5%;Q2,11.1%;Q3,11.2%;Q4,10.3%;P<0.001)或PCR较高(Q1,15.2%;Q2,12.3%;Q3,11.7%;Q4,9.0%;P<0.001)时,累积CV死亡率较高。同样,eGFR较低(Q1,12.7%;Q2,8.4%;Q3,6.7%;Q4,6.1%;P<0.001)或PCR较高(Q1,10.3%;Q2,7.9%;Q3,9.4%;Q4,6.4%;P=0.01)时,非CV死亡率较高。eGFR较低时猝死率高1.7倍(P=0.04);PCR较高时猝死率高2.1倍(P<0.001)。最低eGFR四分位数组的感染相关死亡率高3.3倍(P<0.001),最高PCR四分位数组的感染相关死亡率高2.8倍(P<0.02)。不同eGFR或PCR四分位数组中CV和非CV死亡的总体比例无显著差异。

局限性

结果可能不适用于非糖尿病性CKD或无贫血的糖尿病性CKD。无法获得测量的GFR。

结论

在糖尿病性CKD中,较低的基线GFR和较高的PCR均与较高的CV和非CV死亡率相关,尤其是猝死和感染导致的死亡率。改善预后的努力应侧重于心血管疾病以及感染的早期诊断和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/4549188/1378504a27a6/nihms-686213-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/4549188/b3c63d44732c/nihms-686213-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/4549188/1378504a27a6/nihms-686213-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/4549188/b3c63d44732c/nihms-686213-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/4549188/1378504a27a6/nihms-686213-f0002.jpg

相似文献

1
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).参与促红细胞生成素治疗减少心血管事件试验(TREAT)的糖尿病慢性肾脏病患者的死亡原因
Am J Kidney Dis. 2015 Sep;66(3):429-40. doi: 10.1053/j.ajkd.2015.02.324. Epub 2015 Apr 29.
2
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.贫血、CKD 和 2 型糖尿病患者的血红蛋白稳定性:阿法依泊汀治疗(TREAT)安慰剂臂分析。
Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16.
3
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).促红细胞生成素治疗降低心血管事件试验(TREAT)的基线特征。
Am J Kidney Dis. 2009 Jul;54(1):59-69. doi: 10.1053/j.ajkd.2009.04.008. Epub 2009 Jun 5.
4
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).在开始透析前使用达贝泊汀治疗贫血和临床结局:来自用阿法依泊汀治疗降低心血管事件试验(TREAT)的分析。
Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.
5
Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study.慢性肾脏病患者血清氯水平与死亡率及心血管事件的关联:CKD-ROUTE研究
Clin Exp Nephrol. 2017 Feb;21(1):104-111. doi: 10.1007/s10157-016-1261-0. Epub 2016 Apr 4.
6
Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).一项随机对照试验的原理与研究设计,该试验旨在评估使用阿法依泊汀维持血红蛋白水平对预防非糖尿病慢性肾脏病患者终末期肾病发生的影响(PREDICT试验)。
Clin Exp Nephrol. 2016 Feb;20(1):71-6. doi: 10.1007/s10157-015-1133-z. Epub 2015 Jun 17.
7
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.达比加群酯与促红细胞生成素α在开始血液透析的终末期肾病患者中的长期疗效比较:一项准实验队列研究。
Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2.
8
Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.2型糖尿病非白蛋白尿性慢性肾脏病患者肾功能快速下降、全因死亡率及主要心血管事件的风险
Diabetes Care. 2020 Jan;43(1):122-129. doi: 10.2337/dc19-1438. Epub 2019 Dec 3.
9
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).C反应蛋白与终末期肾病风险:促红细胞生成素治疗减少心血管事件试验(TREAT)的结果
Am J Kidney Dis. 2016 Dec;68(6):873-881. doi: 10.1053/j.ajkd.2016.07.022. Epub 2016 Sep 16.
10
Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.定义慢性肾脏病对 2 型糖尿病患者全因死亡率的影响:肾功能不全和心血管事件(RIACE)意大利多中心研究。
Acta Diabetol. 2018 Jun;55(6):603-612. doi: 10.1007/s00592-018-1133-z. Epub 2018 Mar 24.

引用本文的文献

1
The mortality of chronic kidney disease in Chinese subjects: a 12-year cohort based on clinical data in electronic health record.中国慢性肾脏病患者的死亡率:基于电子健康记录临床数据的12年队列研究
Ann Med. 2025 Dec;57(1):2540021. doi: 10.1080/07853890.2025.2540021. Epub 2025 Aug 6.
2
Kidney status and events preceding death in heart failure: A real-world nationwide study.心力衰竭患者死亡前的肾脏状况及相关事件:一项全国性真实世界研究。
Eur J Heart Fail. 2025 Jun;27(6):982-990. doi: 10.1002/ejhf.3631. Epub 2025 Mar 2.
3
Animal models of membranous nephropathy: more choices and higher similarity.

本文引用的文献

1
Associations between hemodialysis access type and clinical outcomes: a systematic review.血液透析通路类型与临床结局的关联:系统评价。
J Am Soc Nephrol. 2013 Feb;24(3):465-73. doi: 10.1681/ASN.2012070643. Epub 2013 Feb 21.
2
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.患有和不患有糖尿病者的肾脏疾病指标与死亡率和终末期肾病的相关性:一项荟萃分析。
Lancet. 2012 Nov 10;380(9854):1662-73. doi: 10.1016/S0140-6736(12)61350-6. Epub 2012 Sep 24.
3
Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.
膜性肾病的动物模型:更多选择,更高相似度。
Front Immunol. 2024 Oct 21;15:1412826. doi: 10.3389/fimmu.2024.1412826. eCollection 2024.
4
Interventions for fatigue in people with kidney failure requiring dialysis.肾衰竭需透析患者的疲劳干预措施。
Cochrane Database Syst Rev. 2023 Aug 31;8(8):CD013074. doi: 10.1002/14651858.CD013074.pub2.
5
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.促红细胞生成素刺激剂治疗慢性肾脏病成人贫血的网状 Meta 分析。
Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.
6
Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial.缺血性肾病-慢性肾脏病(ISCHEMIA-CKD)试验中晚期慢性肾脏病患者的病因特异性死亡率。
JACC Cardiovasc Interv. 2023 Jan 23;16(2):209-218. doi: 10.1016/j.jcin.2022.10.062.
7
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.非奈利酮与慢性肾病和 2 型糖尿病患者的死亡率:FIDELITY 分析。
Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):183-191. doi: 10.1093/ehjcvp/pvad001.
8
Impact of albuminuria on the various causes of death in diabetic patients: a nationwide population-based study.白蛋白尿对糖尿病患者各种死因的影响:一项全国范围内基于人群的研究。
Sci Rep. 2023 Jan 6;13(1):295. doi: 10.1038/s41598-022-23352-0.
9
Patterns of microbial resistance in bloodstream infections of hemodialysis patients: a cross-sectional study from Palestine.血液透析患者血流感染中微生物耐药模式:来自巴勒斯坦的一项横断面研究。
Sci Rep. 2022 Oct 26;12(1):18003. doi: 10.1038/s41598-022-21979-7.
10
Decreased Peripheral Naïve T Cell Number and Its Role in Predicting Cardiovascular and Infection Events in Hemodialysis Patients.外周血初始 T 细胞数量减少及其在预测血液透析患者心血管和感染事件中的作用。
Front Immunol. 2021 Mar 17;12:644627. doi: 10.3389/fimmu.2021.644627. eCollection 2021.
估算肾小球滤过率和白蛋白尿作为高心血管风险患者结局的预测指标:一项队列研究。
Ann Intern Med. 2011 Mar 1;154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005.
4
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.估算肾小球滤过率降低和白蛋白尿升高与全因和心血管死亡率相关。高危人群队列的协作荟萃分析。
Kidney Int. 2011 Jun;79(12):1341-52. doi: 10.1038/ki.2010.536. Epub 2011 Feb 9.
5
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.估算肾小球滤过率降低和白蛋白尿升高与死亡率和终末期肾病相关。肾脏病患者队列的协作荟萃分析。
Kidney Int. 2011 Jun;79(12):1331-40. doi: 10.1038/ki.2010.550. Epub 2011 Feb 2.
6
US Renal Data System 2010 Annual Data Report.美国肾脏数据系统2010年年报。
Am J Kidney Dis. 2011 Jan;57(1 Suppl 1):A8, e1-526. doi: 10.1053/j.ajkd.2010.10.007.
7
Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.慢性肾脏病与主要心血管疾病和非血管性死亡风险:前瞻性基于人群的队列研究。
BMJ. 2010 Sep 30;341:c4986. doi: 10.1136/bmj.c4986.
8
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.估算肾小球滤过率和白蛋白尿与普通人群全因和心血管死亡率的关系:荟萃分析协作研究。
Lancet. 2010 Jun 12;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5. Epub 2010 May 17.
9
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.阿法达贝泊汀治疗2型糖尿病和慢性肾病的一项试验。
N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.
10
Cardiovascular and noncardiovascular mortality among patients starting dialysis.开始透析的患者的心血管和非心血管死亡率。
JAMA. 2009 Oct 28;302(16):1782-9. doi: 10.1001/jama.2009.1488.